Publisher of Iranian Journals and Conference Proceedings

Please waite ..
Publisher of Iranian Journals and Conference Proceedings
Login |Register |Help |عضویت کتابخانه ها
Paper
Title

High-dose dual therapy with a clavulanic acid component for Helicobacter pylori infection treatment: A Randomized Controlled Trial

Year: 1400
COI: HSEBCNF04_021
Language: EnglishView: 112
This Paper With 6 Page And PDF Format Ready To Download

Buy and Download

با استفاده از پرداخت اینترنتی بسیار سریع و ساده می توانید اصل این Paper را که دارای 6 صفحه است به صورت فایل PDF در اختیار داشته باشید.
آدرس ایمیل خود را در کادر زیر وارد نمایید:

Authors

Arezoo Delshad - Department of internal medicine, Urmia University of Medical Science, Urmia, Iran.
Mohammad Reza Mohammad Hoseiniazar - Department of internal medicine, Gastroenterology and Hepatology section, Urmia University of Medical Science, Urmia, Iran.
Mohammad Reza Pashaei - Department of internal medicine, Gastroenterology and Hepatology section, Urmia University of Medical Science, Urmia, Iran.

Abstract:

Background: Several drug regimens such as Dual and quadruple therapy are used to eradicate Helicobacter pylori. This study was performed to compare the Dual therapy (DT) regimen (Rabeprazole, Amoxicillin, and Co-Amoxiclav) and the quadruple therapy (QT) regimen group (Rabeprazole, Amoxicillin, Metronidazole, and Bismuth) to eradicate Helicobacter pylori (H. pylori).Methods: ۲۲۰ eligible patients were included in the study (۱۰۸ in the DT and ۱۱۲ in the QT group). Randomization will be performed in a simple randomization method by using a table of random numbers and patients were divided into two groups. The DT regimen consisted of amoxicillin ۵۰۰ mg three times daily (TDS) with Co-amoxiclav ۶۲۵ mg TDS and Rabeprazole ۲۰ mg TDS for two weeks. The standard QT regimen included amoxicillin ۱۰۰۰ mg twice daily (BID), bismuth ۵۰۰ mg BID, metronidazole ۵۰۰ mg BID, and rabeprazole BID for two weeks. Two weeks after the end of the treatment period, patients were evaluated for eradication of H. pylori with H. pylori stool antigen test.Results: ۱۰۴ patients in the DT group and ۱۰۶ people in the QT group were able to complete the treatment course. The eradication rate was ۸۶.۵۴% (n = ۹۰) and ۸۸.۴۶% (n = ۹۲) in the quadruple and dual drug treatment groups, respectively. No significant difference was observed between the two groups in H. pylori eradication rate (P=۰.۵۴۴).Conclusion: According to this study, it can be concluded that adding the clavulanic acid component to the eradication regimen has no effect and is not recommended.

Keywords:

Helicobacter pylori , Rabeprazole , Co-amoxiclav , High dose dual drug therapy

Paper COI Code

This Paper COI Code is HSEBCNF04_021. Also You can use the following address to link to this article. This link is permanent and is used as an article registration confirmation in the Civilica reference:

https://civilica.com/doc/1302574/

How to Cite to This Paper:

If you want to refer to this Paper in your research work, you can simply use the following phrase in the resources section:
Delshad, Arezoo and Mohammad Hoseiniazar, Mohammad Reza and Pashaei, Mohammad Reza,1400,High-dose dual therapy with a clavulanic acid component for Helicobacter pylori infection treatment: A Randomized Controlled Trial,Fourth National Conference on Safety and Health,Tehran,https://civilica.com/doc/1302574

Research Info Management

Certificate | Report | من نویسنده این مقاله هستم

اطلاعات استنادی این Paper را به نرم افزارهای مدیریت اطلاعات علمی و استنادی ارسال نمایید و در تحقیقات خود از آن استفاده نمایید.

Scientometrics

The specifications of the publisher center of this Paper are as follows:
Type of center: دانشگاه دولتی
Paper count: 15,228
In the scientometrics section of CIVILICA, you can see the scientific ranking of the Iranian academic and research centers based on the statistics of indexed articles.

New Papers

New Researchs

Share this page

More information about COI

COI stands for "CIVILICA Object Identifier". COI is the unique code assigned to articles of Iranian conferences and journals when indexing on the CIVILICA citation database.

The COI is the national code of documents indexed in CIVILICA and is a unique and permanent code. it can always be cited and tracked and assumed as registration confirmation ID.

Support